<DOC>
	<DOCNO>NCT00269802</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety OROSÂ® Methylphenidate HCl compare placebo standard immediate-release RitalinÂ® ( take three time per day ) treatment Attention Deficit Hyperactivity Disorder child . Both OROSÂ® Methylphenidate HCl RitalinÂ® contain central nervous system stimulant , methylphenidate HCl .</brief_summary>
	<brief_title>A Multicenter Study Comparing Efficacy Safety OROS Methylphenidate HCl , Ritalin ( Methylphenidate HCl ) Placebo Children With Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>Attention Deficit Hyperactivity Disorder ( ADHD ) represent common neurobehavioral disorder child , affect 3 % 5 % school-age population . Behavioral pediatrician , child psychiatrist , child neurologist indicate referral ADHD may constitute 50 % practice . This multicenter , double-blind , double-dummy , randomize , placebo-controlled , active-controlled , three-treatment , parallel group study evaluate efficacy safety OROS® ( methylphenidate HCl ) standard immediate-release Ritalin® ( three time day ) , placebo , child ADHD . Patients assign one three treatment , depend upon prestudy titrate therapeutic dose regimen , treat 28 day . Patients give OROS® ( methylphenidate HCl ) , 18 , 36 54 milligram daily , Ritalin® 5 , 10 , 15 milligram ( encapsulated/single capsule ) three time day , placebo . Efficacy evaluate community set teacher , parent investigator use standardized attention behavior scale assessment . The primary measure effectiveness teacher 's rating study Day 27 IOWA Conners Inattention/Overactivity subscale . Additional measure effectiveness include IOWA Conners Oppositional/Defiance subscale rating , peer interaction behavioral rating , SNAP-IV rating , global assessment efficacy , investigator Clinical Global Impression ( CGI ) , home situation parent satisfaction questionnaire . Safety evaluation include incidence adverse event , physical examination , clinical laboratory test , vital sign , sleep quality , appetite , presence/severity tic ( hard-to-control , repeat twitch part body hard-to-control repeat sound word ) . Patients give orally 28 day : OROS® ( methylphenidate HCl ) , 1 , 2 , 3 18 milligram tablet daily , Ritalin® 5 , 10 , 15 milligram ( encapsulated/single capsule ) three time daily , placebo</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Patients successfully complete ALZA screen protocol C98011 within past six month take take past 5 20 mg immediaterelease methylphenidate ( Ritalin® ) least twice day , 20 60 mg sustainedrelease methylphenidate ( RitalinSR® ) per day , combination immediaterelease sustainedrelease methylphenidate daily dose exceed 60 mg , successfully complete ALZA Protocol C98007 agree take supplied study drug treatment ADHD fourweek treatment phase study able comply study visit schedule whose parent ( ) teacher willing able complete protocolspecified assessment normal urinalysis , hematological blood chemistry value , value outside normal range , determine clinically significant investigator Patients clinically significant gastrointestinal problem , include narrow gastrointestinal tract glaucoma , ongoing seizure disorder , psychotic disorder , clinical depression ( suicidal require immediate treatment depression ) , diagnosis Tourette 's syndrome know allergy methylphenidate currently significant adverse experience methylphenidate mean two blood pressure measurement ( systolic diastolic ) equal great 95th percentile age , sex , height screen female , begin menstruation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>OROS®</keyword>
	<keyword>Ritalin®</keyword>
	<keyword>child</keyword>
	<keyword>methylphenidate</keyword>
</DOC>